British-German Alliance for Advanced Therapies

You are invited to take part in the British-German Alliance for Advanced Therapies scientific meeting on Tuesday 26 March 2019, 11.00-19.00. This meeting is jointly hosted by the Cell and Gene Therapy Catapult (CGT Catapult), the UK's Science and Innovation Network, Charité and partners.

The day comprises a series of talks covering key technical themes for the manufacture of advanced therapies led by British and German cell and gene therapy experts. We also welcome you to join us for the evening networking dinner. This is an opportunity to meet fellow researchers and companies working in the field and hear about opportunities for international collaboration between Germany and the UK.

We hope you will be able to join us. Spaces are limited so please make sure that you RSVP by registering for free above.

Please email comms@ct.catapult.org.uk if you have any queries.

Please note that you will need to bring valid photo identification to access the event (e.g. passport, driving license, national identity card).

Agenda:

• 11.00-12.00, Registration

• 12.00-12.10, Welcome introductions, UK's Department for International Trade and Science Innovation Networking

• 12.10-12.20, Charité welcome address, Friedemann Paul, Director of ECRC and Representative for International Affairs

• 12.20-12.30, Stiftung Charité, André Lottmann, Head of Science Founding

• 12.30-12.40, Berlin Institute of Health (BIH), Xenia Boergen, Head of Law, Patents and Licenses

• 12.40-13.10, Introduction to CGT Catapult: our strategy and the UK Ecosystem, Dr Jonathan Appleby, Chief Scientific Officer, CGT Catapult

• 13.10-13.40, EU large scale research initiative “RESTORE” – health by advanced therapies, Hans-Dieter Volk, Director of BCRT & RESTORE Coordinator

• 13.40-14.10, “ReSHAPE” by next generation Treg approaches – An EU Consortium coordinated by BeCAT, Petra Reinke, Director of BeCAT & ReSHAPE Coordinator

• 14.10-14.30, Viral vector process development, Mike Delahaye, Lead Scientist, CGT Catapult

• 14.30-14.55, ATMP manufacturing and translation: the view of Miltenyi Biotech, Michael Apel, Head of Project Management, Grants & Cooperation

• 14.55-15.35, Coffee break

• 15.35-16.00, CAR T-cell Therapy – opportunities & challenges for curing haematological malignancies, Michael Bergwelt, Director of Medical Clinic III, LMU

• 16.00-16.20, Advanced preclinical models by application of human-on-the-chip technology, Uwe Marx, Chief Scientific Officer, TissUSE

• 16.20-16.40, iPSC technology for disease modelling and therapeutic cell source, Harald Stachelscheid, Leader BIH Core Facility Stem Cells and Daniel Besser, Coordinator German Stem Cell Network (GSTN)

• 16.40-17.00, Application of gene editing CRISPR in ATMP manufacturing, Tristan Thwaites, Lead Scientist, CGT Catapult

• 17.00-17.20, Preexisting immunity to CAS-proteins – How can we overcome these challenges?, Michael Schmück-Henneresse, Junior Group Leader BCRT/BeCAT

• 17.20-17.40, Personalized 3D printed heart valves, Boris Schmitt, Research Group Leader German Heart Center, Founder KidCathLab, Innovation Project Leader GrOwnValve

• 17.40-18.00, Multimodal data handling opportunities challenges and solutions, Marc-Olivier Baradez, Lead Scientist, CGT Catapult

• 18.00, Networking dinner